Ron joined Abingworth in July 2026 and works with the Clinical Co-Development team, evaluating new investment opportunities and supporting existing investments. Prior to joining Abingworth, Ron spent a year at Abingworth portfolio company Launch Therapeutics, where he evaluated clinical co-development opportunities.
Previously, Ron led public and private biopharma investments at the Qatar Investment Authority. He was also a research analyst covering public biopharmaceutical companies at Millennium Management and Artisan Partners.
Ron holds an MD from New York Medical College and a BA in Biochemistry from Harvard College.
